RayzeBio (RayzeBio) EBIT : $-39.11 Mil (TTM As of Sep. 2023)

View and export this data going back to 2023. Start your Free Trial

What is RayzeBio EBIT?

RayzeBio's earnings before interest and taxes (EBIT) for the three months ended in Sep. 2023 was $-21.65 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2023 was $-39.11 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. RayzeBio's annualized ROC % for the quarter that ended in Sep. 2023 was -155.42%. RayzeBio's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2023 was -169.37%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. RayzeBio's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2023 was -1.21%.

RayzeBio EBIT Historical Data

The historical data trend for RayzeBio's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RayzeBio EBIT Chart

RayzeBio Annual Data

Trend

Dec20

Dec21

Dec22

EBIT

-6.92

-39.38

-72.12

RayzeBio Quarterly Data
	Dec20	Dec21	Jun22	Sep22	Dec22	Jun23	Sep23
EBIT	Get a 7-Day Free Trial			-	-20.95	-17.46	-	-21.65

Competitive Comparison of RayzeBio's EBIT

For the Biotechnology subindustry, RayzeBio's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

RayzeBio's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, RayzeBio's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where RayzeBio's EV-to-EBIT falls into.

RayzeBio EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-39.11 Mil.

RayzeBio (NAS:RYZB) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

RayzeBio's annualized ROC % for the quarter that ended in Sep. 2023 is calculated as:

	ROC % (Q: Sep. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Jun. 2023 )	+	Invested Capital (Q: Sep. 2023 ))	/ count )
=	-86.604 * ( 1 - 0% )	/	( (48.574	+	62.869)	/ 2 )
=	-86.604	/	55.7215
=	-155.42 %

where

	Invested Capital		(Q: Jun. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	305.762	-	11.3	-	( 256.954	-	max(0, 14.658	-	260.546	+	256.954	))
=	48.574

	Invested Capital		(Q: Sep. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	603.513	-	12.771	-	( 540.169	-	max(0, 17.113	-	544.986	+	540.169	))
=	62.869

Note: The Operating Income data used here is four times the quarterly (Sep. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

RayzeBio's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Sep. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Jun. 2023		Q: Sep. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-86.604	/	( ( (44.085 + max(-9.841, 0))	+	(58.18 + max(-11.03, 0)) )	/	2 )
=	-86.604	/	( ( 44.085	+	58.18 )	/	2 )
=	-86.604	/	51.1325
=	-169.37 %

where Working Capital is:

	Working Capital		(Q: Jun. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	3.592)	-	(11.3	+	0	+	2.133)
=	-9.841

	Working Capital		(Q: Sep. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	4.817)	-	(12.771	+	0	+	3.076)
=	-11.03

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

RayzeBio's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Sep. 2023 )
	=	-39.111	/	3219.979
	=	-1.21 %

RayzeBio EBIT Related Terms

Thank you for viewing the detailed overview of RayzeBio's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

RayzeBio (RayzeBio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RayzeBio inc (NAS:RYZB) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

5505 Morehouse Drive, Suite 300, San Diego, CA, USA, 92121

Website

https://www.rayzebio.com

RayzeBio inc is a company operating as vertically integrated radiopharmaceutical therapeutics company. The main objective of the company is defeating cancer with radiopharmaceutical medicines. It has a created a pipeline of multiple drug candidates, in therapeutic areas with significant market opportunities. They have a portfolio of potential RPT drug and development candidates that includes late-stage clinical programs, development programs and discovery programs.

Executives

Hauwermeiren Timothy Van	director	C/O ITEOS THERAPEUTICS, INC., 139 MAIN STREET, CAMBRIDGE MA 02142
Viking Global Investors Lp	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Maha Katabi	director	SOFINNOVA INVESTMENTS, 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Viking Global Opportunities Drawdown Gp Llc	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Opportunities Drawdown Portfolio Gp Llc	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Arvind Kush	officer: Chief Financial Officer	C/O RAYZEBIO, INC., 5505 MOREHOUSE DRIVE, SUITE 300, SAN DIEGO CA 92121
Wellington Biomedical Innovation Master Investors (cayman) Ii L.p.	10 percent owner	280 CONGRESS STREET, BOSTON MA 02210
Versant Ventures Vii Gp-gp, Llc	10 percent owner	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Versant Ventures Vii Gp, L.p.	10 percent owner	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Kenneth Song	director, officer: President and Chief Executive	C/O RAYZEBIO, INC., 5505 MOREHOUSE DRIVE, SUITE 300, SAN DIEGO CA 92121
Susan Moran	officer: Chief Medical Officer	1232 RICHARDSON AVE, LOS ALTOS CA 94024
Venbio Global Strategic Gp Iii, L.p.	10 percent owner	1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158
Venbio Global Strategic Gp Iii, Ltd	10 percent owner	1700 OWENS STREET, SUITE 595, SAN FRANCISCI CA 94158
Venbio Global Strategic Fund Iii, L.p.	10 percent owner	1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158
Redmile Biopharma Investments Ii, L.p.	10 percent owner	LETTERMAN DIGITAL ARTS CENTER, ONE LETTERMAN DRIVE, SUITE D3-300, SAN FRANCISCO CA 94129